Complete remission rates in relation to defined subgroups, significance levels for differences between subgroups from univariate analyses, adjusted odds ratios after controlling for the influence of the other significant risk factors, corresponding 95% confidence intervals (CIs), and significance levels from multivariate logistic regression
| Parameter/subgroup . | Univariate analysis . | Multivariate analysis . | |||
|---|---|---|---|---|---|
| Percentage CR . | P (χ2 test) . | Adjusted OR . | 95% CI . | P (Wald test) . | |
| Karyotype | |||||
| Intermediate risk | 52.7 | 1 | |||
| Favorable risk | 81.6 | 5.54 | 2.34-13.15 | < .001 | |
| High risk | 33.0 | < .001 | 0.50 | 0.34-0.72 | < .001 |
| NPM1/FLT3 status | |||||
| NPM−/FLT3−ITD− | 43.0 | 1 | |||
| NPM+/FLT3−ITD− | 67.9 | 2.49 | 1.48-4.18 | .001 | |
| NPM+/FLT3−ITD+ | 69.2 | 3.09 | 1.71-5.59 | < .001 | |
| NPM−/FLT3−ITD+ | 41.5 | < .001 | 1.10 | 0.60-2.00 | .761 |
| CD34 expression | |||||
| Less than or equal to 10% | 64.1 | 1 | |||
| More than 10% | 43.0 | < .001 | 0.55 | 0.38-0.80 | .001 |
| Age, y | |||||
| 61-65 | 57.1 | 1 | |||
| More than 65 | 54.1 | < .001 | 0.62 | 0.46-0.82 | .001 |
| WBC, /μL | |||||
| Less than or equal to 20 | 53.6 | 1 | |||
| More than 20 | 44.0 | .005 | 0.55 | 0.39-0.77 | .001 |
| LDH, U/L | |||||
| Less than or equal to 700 | 53.6 | 1 | |||
| More than 700 | 42.5 | .005 | 0.62 | 0.43-0.90 | .011 |
| BM blasts day 15 | |||||
| Less than or equal to 10% | 58.6 | 1 | |||
| More than 10% | 46.9 | .005 | 0.65 | 0.45-0.93 | .019 |
| ECOG | |||||
| Less than or equal to 2 | 52.8 | ||||
| More than 2 | 35.4 | .003 | — | — | — |
| Disease status | |||||
| De novo | 52.6 | ||||
| Secondary | 42.4 | .007 | — | — | — |
| Sex | |||||
| Male | 50.3 | ||||
| Female | 49.5 | .815 | — | — | — |
| Parameter/subgroup . | Univariate analysis . | Multivariate analysis . | |||
|---|---|---|---|---|---|
| Percentage CR . | P (χ2 test) . | Adjusted OR . | 95% CI . | P (Wald test) . | |
| Karyotype | |||||
| Intermediate risk | 52.7 | 1 | |||
| Favorable risk | 81.6 | 5.54 | 2.34-13.15 | < .001 | |
| High risk | 33.0 | < .001 | 0.50 | 0.34-0.72 | < .001 |
| NPM1/FLT3 status | |||||
| NPM−/FLT3−ITD− | 43.0 | 1 | |||
| NPM+/FLT3−ITD− | 67.9 | 2.49 | 1.48-4.18 | .001 | |
| NPM+/FLT3−ITD+ | 69.2 | 3.09 | 1.71-5.59 | < .001 | |
| NPM−/FLT3−ITD+ | 41.5 | < .001 | 1.10 | 0.60-2.00 | .761 |
| CD34 expression | |||||
| Less than or equal to 10% | 64.1 | 1 | |||
| More than 10% | 43.0 | < .001 | 0.55 | 0.38-0.80 | .001 |
| Age, y | |||||
| 61-65 | 57.1 | 1 | |||
| More than 65 | 54.1 | < .001 | 0.62 | 0.46-0.82 | .001 |
| WBC, /μL | |||||
| Less than or equal to 20 | 53.6 | 1 | |||
| More than 20 | 44.0 | .005 | 0.55 | 0.39-0.77 | .001 |
| LDH, U/L | |||||
| Less than or equal to 700 | 53.6 | 1 | |||
| More than 700 | 42.5 | .005 | 0.62 | 0.43-0.90 | .011 |
| BM blasts day 15 | |||||
| Less than or equal to 10% | 58.6 | 1 | |||
| More than 10% | 46.9 | .005 | 0.65 | 0.45-0.93 | .019 |
| ECOG | |||||
| Less than or equal to 2 | 52.8 | ||||
| More than 2 | 35.4 | .003 | — | — | — |
| Disease status | |||||
| De novo | 52.6 | ||||
| Secondary | 42.4 | .007 | — | — | — |
| Sex | |||||
| Male | 50.3 | ||||
| Female | 49.5 | .815 | — | — | — |
— indicates not applicable.